Recent Articles
When Data Meets Doubt: Investigating the FDA Panel’s Rejection of MDMA
MAPS/Lykos’ MDMA trials for PTSD delivered overwhelmingly positive results. I thought that mattered until I sat through a nine-hour deliberation among the FDA’s Psychopharmacologic Drugs Advisory Committee on June 4, including two hours of public comments that skewed anti-Lykos. After a long day of groupthink, the panel advised the FDA that MDMA therapy was neither […]
By Elena Schmidt
Archetypes, Individuation, and the Shadow: Carl Jung’s Enduring Psychedelic Influence
By Adam Miezio
Filter
Raising the Bar: Why Psychedelic Mentorship is Essential For Professional Development
Asking for help is an inherently vulnerable thing. But when it comes to becoming a…
By Jason Najum
Understanding Microdosing: Integrating Small Doses for Big Therapeutic Gains
Microdosing. By now the practice has fully emerged from the underground and into the mainstream.…
By Jason Najum
What is MDMA’s FDA Approval Status? A Look Ahead
Following the multi-decade regulatory pursuit, legal MDMA-assisted therapy (MDMA-AT) seemed imminent to many people. In…
By Elena Schmidt
Expanding Psychedelic Clinical Trials to LGBTQ+ Populations
Explore how expanding psychedelic clinical trials to include LGBTQ+ populations can address mental health disparities…
By Brady D. Hanshaw, Chase T.M. Anderson, MD, Mark Fusunyan, and Jack L. Turban, MD, MHS
Why Are Some Parents Choosing Psychedelics Over SSRIs for Teens?
Disclaimer: The content of this article does not constitute medical advice. At the time of…
By Elena Schmidt
Psychedelic Bypassing: When Avoidance is Mistaken for Healing
Psychedelic Bypassing: The many ways the mind can excuse abuse, ignore the darker sides of…